The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 22: 3015 - 3020

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.22.028

Reviews

Clinical research progress of bexagliflozin： A new hypoglycemic drug

  • Yan YANG ,
  • Zhen WANG ,
  • Defeng. WANG
Expand
  • *.Clinical Medical College. Hebei University of Engineering，Handan 056000，China

Received date: 2023-07-24

  Online published: 2023-12-11

Fold

Abstract

Several drugs have been developed for the treatment of diabetes， but many patients still fail to achieve ideal glycemic control. In January 2023， the U.S. Food and Drug Administration （FDA） approved the marketing of the sodium-glucose cotransporter 2 inhibitor， bexagliflozin， for use to improve glycemic control in adults with type 2 diabetes as an adjunctive therapy to diet and exercise. The drug has been shown to be effective and safe in the treatment of diabetes mellitus. Several clinical studies have demonstrated its efficacy and safety in type 2 diabetes， and it also has potential applications in the treatment of obesity， cardiovascular disease， and chronic kidney disease. This article summarizes the mechanism of action， clinical studies， efficacy and safety of bexagliflozin to provide reference for its clinical application in China.

Key words： type 2 diabetes mellitus; bexagliflozin; SGLT-2; review

Cite this article

Yan YANG , Zhen WANG , Defeng. WANG . Clinical research progress of bexagliflozin： A new hypoglycemic drug[J]. The Journal of Practical Medicine, 2023 , 39(22) : 3015 -3020 . DOI: 10.3969/j.issn.1006-5725.2023.22.028

References

1 SUN H， SAEEDI P， KARURANGA S， et al. IDF Diabetes Atlas： Global， regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 ［J］. Diabetes Res Clin Pract， 2022， 183： 109119.
2 中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）（上）［J］. 中国实用内科杂志. 2021， 41（8）： 668-695.
3 LIM L L， CHOW E， CHAN J C N. Cardiorenal diseases in type 2 diabetes mellitus： clinical trials and real-world practice ［J］. Nat Rev Endocrinol， 2023， 19（3）： 151-163.
4 RIEG T， VALLON V. Development of SGLT1 and SGLT2 inhibitors ［J］. Diabetologia， 2018， 61（10）： 2079-2086.
5 VADUGANATHAN M， DOCHERTY K F， CLAGGETT B L， et al. SGLT-2 inhibitors in patients with heart failure： a comprehensive meta-analysis of five randomised controlled trials ［J］. Lancet， 2022， 400（10354）： 757-767.
6 SOLOMON J， FESTA M C， CHATZIZISIS Y S， et al. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease ［J］. Pharmacol Ther， 2023， 242： 108330.
7 THERACOSBIO. Theracos Bio announces FDA approval of Brenzavvy? （bexaglifozin） for the treatment of adults with type 2 diabetes［EB/OL］.（2023-01-23）［2023-11-28］..
8 ALLEGRETTI A S， ZHANG W， ZHOU W， et al. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD ［J］. Am J Kidney Dis， 2019， 74（3）： 328-337.
9 HALVORSEN Y D， WALFORD G， THURBER T， et al. A 12-week， randomized， double-blind， placebo-controlled， four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes ［J］. Diabetes Obes Metab， 2020， 22（4）： 566-573.
10 ZHANG W， LI X， DING H， et al. Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats， monkeys and humans ［J］. Xenobiotica， 2020， 50（5）： 559-569.
11 THERACOSBIO LLC. BRENZAVVY （bexaglifozin） tablets， for oral use： US prescribinginformation［EB/OL］. （2023-09-13）［2023-11-28］..
12 BROWN E， HEERSPINK H J L， CUTHBERTSON D J， et al. SGLT2 inhibitors and GLP-1 receptor agonists： established and emerging indications ［J］. Lancet， 2021， 398（10296）： 262-276.
13 D'ANDREA E， WEXLER D J， KIM S C， et al. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels ［J］. JAMA Intern Med， 2023， 183（3）： 242-254.
14 KANG S M， YUN H M， SOHN M， et al. Vascular and metabolic effects of ipragliflozin versus sitagliptin （IVS） in type 2 diabetes treated with sulphonylurea and metformin： IVS study ［J］. Diabetes Obes Metab， 2023， 25（7）： 1922-1931.
15 HALVORSEN Y C， WALFORD G A， MASSARO J， et al. A 96-week， multinational， randomized， double-blind， parallel-group， clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes ［J］. Diabetes Obes Metab， 2019， 21（11）： 2496-2504.
16 HALVORSEN Y D， LOCK J P， FRIAS J P， et al. A 96-week， double-blind， randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults ［J］. Diabetes Obes Metab， 2023， 25（1）： 293-301.
17 HALVORSEN Y D， CONERY A L， LOCK J P， et al. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults： A 24-week， randomized， double-blind， placebo-controlled trial ［J］. Diabetes Obes Metab， 2023，25（10）：2954-2962.
18 HALVORSEN Y D， LOCK J P， ZHOU W， et al. A 24-week， randomized， double-blind， active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults ［J］. Diabetes Obes Metab， 2019， 21（10）： 2248-2256.
19 MCMURRAY J J V， FREEMAN M W， MASSARO J， et al. 32-OR： The Bexagliflozin Efficacy and Safety Trial （BEST）： A Randomized， Double-Blind， Placebo-Controlled， Phase IIII， Clinical Trial ［J］. Diabetes， 2020， 69（）： 32-OR.
20 PASQUALOTTO E， FIGUEIREDO WATANABE J M， GEWEHR D M， et al. Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus： A systematic review and meta-analysis ［J］. Diabetes Obes Metab， 2023， 25（7）： 1794-1802.
21 XU B， LI S， KANG B， et al. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management ［J］. Cardiovasc Diabetol， 2022， 21（1）： 83.
22 SPERTUS J A， BIRMINGHAM M C， NASSIF M， et al. The SGLT2 inhibitor canagliflozin in heart failure： the CHIEF-HF remote， patient-centered randomized trial ［J］. Nat Med， 2022， 28（4）： 809-813.
23 SARRAJU A， BAKRIS G， CANNON C P， et al. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria ［J］. J Am Coll Cardiol， 2022， 80（18）： 1721-1731.
24 HEERSPINK H J L， OSHIMA M， ZHANG H， et al. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD： Findings From the Randomized CREDENCE Trial ［J］. Am J Kidney Dis， 2022， 79（2）：244-256.e1.
25 SOLOMON S D， MCMURRAY J J V， CLAGGETT B， et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction ［J］. N Engl J Med， 2022， 387（12）： 1089-1098.
26 JONGS N， GREENE T， CHERTOW G M， et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes： a prespecified analysis from the DAPA-CKD trial ［J］. Lancet Diabetes Endocrinol， 2021， 9（11）： 755-766.
27 BUTT J H， DEWAN P， MERKELY B， et al. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction ： A Post Hoc Analysis of the DAPA-HF Trial ［J］. Ann Intern Med， 2022， 175（6）： 820-830.
28 B?HM M， BUTLER J， FILIPPATOS G， et al. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age ［J］. J Am Coll Cardiol， 2022， 80（1）：1-18.
Options
Outlines

/

〈 〉